Skip to content
To the full analysis

Astellas Pharma stock: balance sheet and debt

4503.T
$16.90Closing price of 13 Nov 2026MEQIRI Score 87 out of 100

Astellas Pharma has a debt to equity ratio of 0.31 and an interest coverage of 27.8x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.31
Interest coverage
27.8x
Current ratio
1.17
Cash & equivalents
$1.76B
Total assets
$22.34B
Equity ratio
51.3%
Goodwill
$2.76B
Plus intangible assets of $6.24B
Net debt
$1.78B

Total assets and equity ratio

How large the balance sheet of Astellas Pharma Inc. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2007$8.98Bnot reported separatelynot reported separately76.7%−$3.17B
2008$8.76B$425.74M$183.59M79.4%−$3.39B
2009$8.15B$365.45M$165.17M79.1%−$3.22B
2010$8.54B$392.99M$138.76M77.3%−$3.36B
2011$8.36B$2.3B$634.05M76.5%−$1.1B
2012$8.77B$1.97B$589.82M72.7%−$1.87B
2013$9.8B$2.81B$674.08M67.8%−$1.65B
2014$10.35B$2.49B$731.17M76.7%−$2.44B
2015$11.23B$2.71B$853.72M73.5%−$2.48B
2016$11.27B$3.07B$943.41M70.0%−$2.25B
2017$11.36B$3.48B$1.06B70.1%−$2.13B
2018$11.64B$3.94B$1.33B68.3%−$2.07B
2019$11.88B$4.11B$1.41B66.3%−$1.94B
2020$14.5B$6.28B$1.74B55.7%$594.51M
2021$14.24B$5.86B$1.78B61.0%−$299.72M
2022$14.61B$5.8B$1.9B62.6%−$646.49M
2023$15.38B$5.58B$2.06B61.4%−$1.11B
2024$22.35B$11.73B$2.62B44.7%$4.2B
2025$20.91B$9.64B$2.6B45.3%$4.69B
2026$22.34B$9.01B$2.76B51.3%$1.78B

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2007$3.18B$6.88B$12.24M0
2008$3.39B$6.95B$00
2009$3.22B$6.45B$00
2010$3.36B$6.6B$7.2M0
2011$1.11B$6.39B$7.22M0
2012$1.87B$6.38B$7.64M0
2013$1.66B$6.65B$7.26M0
2014$2.45B$7.94B$7.18M0
2015$2.48B$8.25B$6.21M0
2016$2.26B$7.88B$7.68M0
2017$2.13B$7.96B$8.79M0
2018$2.08B$7.94B$8.44M0
2019$1.95B$7.88B$7.51M0
2020$1.99B$8.07B$2.59B0.32
2021$2.04B$8.68B$1.74B0.2
2022$1.98B$9.14B$1.33B0.15
2023$2.36B$9.44B$1.25B0.13
2024$2.1B$9.99B$6.3B0.63
2025$1.18B$9.48B$5.87B0.62
2026$1.76B$11.46B$3.54B0.31

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 13 Nov 2026
Latest annual report
Fiscal year 2026, period end 31 Mar 2026
Currency
Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Strong, published since 7 Nov 2026 (in the score history since 2 Jan 2026)
  • Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy